1.	A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1112-CA, 2012-000694-23, NCT01578707
2.	Safety of PCI-32765 in Chronic Lymphocytic Leukemia Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1102-CA, PCI-32765, NCT01105247
3.	Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1109-CA, PCI-32765, NCT01217749
4.	Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Phase: Phase II Type: Treatment Status: Enrolling by invitation Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1103-CA, PCI-32765, NCT01109069
5.	Safety and Efficacy of PCI-32765 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1104-CA, PCI-32765, NCT01236391
6.	Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1106-CA, PCI-32765, NCT01325701
7.	Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2011-0785, NCT01520519
8.	A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100847, PCI-32765MCL2001, 2012-000711-88, NCT01599949
9.	Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 12-015, NCT01614821
10.	Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-04753, NCT00849654
11.	Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1108-CA, PCI-32765, NCT01292135
12.	A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants Phase: Phase I Type: Biomarker/Laboratory analysis Status: Completed Age: 30 to 55 Sponsor: Pharmaceutical / Industry Protocol IDs: CR100885, PCI-32765CLL1004, 2012-002087-27, NCT01674322